{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:27:13Z","timestamp":1790659633935,"version":"4.1.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100025174","name":"Connect","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rademikibart (CBP-201) is a potent, next-generation human monoclonal antibody optimized to bind with high affinity to interleukin-4 receptor subunit alpha.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate rademikibart efficacy and safety, initially dosed every other week (Q2W), and Q2W or every fourth week (Q4W) from week 16, in Chinese adults\/adolescents with moderate-to-severe atopic dermatitis (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SEASIDE CHINA (NCT05017480) was a phase II randomized trial: stage 1 was a 16-week treatment period, and stage 2 comprised 36-week treatment and 8-week follow-up periods. The primary endpoint was the proportion of patients with a validated Investigator Global Assessment Scale for AD score of 0 or 1 (vIGA 0\/1) and \u2265 2-point reduction from baseline at week 16. Overall, 330 patients were randomized 2 : 1 double-blind to receive subcutaneous rademikibart 600\u2005mg on day 1 and 300\u2005mg Q2W from week 2\u201314, or placebo. Predose at week 16, patients were assessed for minimal important change [\u2265 50% improvement from baseline in Eczema Area and Severity Index score (EASI 50)] and rerandomized 1 : 1 double-blind to rademikibart 300\u2005mg Q2W or Q4W.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In stage 1, 29.0% of patients attained vIGA 0\/1 and \u2265 2-point reduction with rademikibart Q2W (P &amp;lt; 0.001) at week 16, without plateauing, vs. 5.9% with placebo. Rapid, significant improvements were also observed with all other rating scales in stage 1, including \u2265 75% improvement from baseline in EASI (EASI 75) (58.6% vs. 22.6%) and \u2265 4-point reduction in Peak Pruritus Numeric Rating Scale (PP-NRS) (36.3% vs. 10.5%) with rademikibart Q2W vs. placebo, respectively, at week 16. In stage 2, week 16 EASI 50 responders from stage 1 continued to improve through week 52 when treated with rademikibart Q2W or Q4W, including vIGA response (Q2W 59.1%; Q4W 62.6%), EASI 75 (Q2W 84.6%; Q4W 84.8%), and \u2265 4-point reduction in PP-NRS (Q2W 60.4%; Q4W 70.3%). Most patients with improvements during rademikibart Q2W therapy at week 16 maintained these responses through week 52 in both the rademikibart Q2W and Q4W groups: vIGA (Q2W 78.0%; Q4W 87.1%), EASI 75 (Q2W 90.1%; Q4W 92.3%) and \u2265 4-point reduction in PP-NRS (Q2W 85.3%; Q4W 94.8%). Injection site reactions were grade 1 (mild). No serious treatment-emergent adverse events (TEAEs) were treatment related. Three patients discontinued rademikibart owing to TEAEs (AD flare, vitiligo, pregnancy).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rademikibart Q2W induced rapid improvements in AD lesions and pruritus during the initial 16 weeks, which were maintained\/improved further with rademikibart Q2W or Q4W across an additional 36 weeks. Rademikibart Q2W and Q4W were similarly efficacious and well tolerated. These findings are compatible with those from the published international phase II rademikibart trial, CBP-201-WW001.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf347","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T11:55:30Z","timestamp":1756554930000},"page":"47-58","source":"Crossref","is-referenced-by-count":5,"title":["Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized phase II trial (S\n                    <u>EASI<\/u>\n                    DE CHINA): initial 2-week dosing, followed by 2-week or 4-week dosing"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-682X","authenticated-orcid":false,"given":"Jianzhong","family":"Zhang","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital, Department of Dermatology , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, George Washington University School of Medicine and Health Sciences , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawang","family":"Guo","sequence":"additional","affiliation":[{"name":"Suzhou Connect Biopharmaceuticals Ltd , Taicang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jili","family":"Yun","sequence":"additional","affiliation":[{"name":"Suzhou Connect Biopharmaceuticals Ltd , Taicang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuban","family":"Pan","sequence":"additional","affiliation":[{"name":"Suzhou Connect Biopharmaceuticals Ltd , Taicang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wei","sequence":"additional","affiliation":[{"name":"Connect Biopharma LLC , San Diego, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7077-7443","authenticated-orcid":false,"given":"Ra\u00fal","family":"Collazo","sequence":"additional","affiliation":[{"name":"Connect Biopharma LLC , San Diego, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"2026010607271257800_ljaf347-B1","doi-asserted-by":"crossref","first-page":"13030\/qt6nj0\u00d75k0","DOI":"10.5070\/D3258045124","article-title":"The prevalence of atopic dermatitis in adults: systematic review on population studies","volume":"25","author":"Mathiesen","year":"2019","journal-title":"Dermatol Online J"},{"key":"2026010607271257800_ljaf347-B2","doi-asserted-by":"crossref","first-page":"adv00160","DOI":"10.2340\/00015555-3510","article-title":"Prevalence and incidence of atopic dermatitis: a systematic review","volume":"100","author":"Bylund","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2026010607271257800_ljaf347-B3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jfma.2020.06.008","article-title":"Taiwanese Dermatological Association consensus for the management of atopic dermatitis: a 2020 update","volume":"120","author":"Chan","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"2026010607271257800_ljaf347-B4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2340\/00015555-0963","article-title":"Prevalence of atopic dermatitis, allergic rhinitis and asthma in Taiwan: a national study 2000 to 2007","volume":"90","author":"Hwang","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"2026010607271257800_ljaf347-B5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/CM9.0000000000002560","article-title":"Prevalence and risk factors of atopic dermatitis in Chinese adults: a nationwide population-based cross-sectional study","volume":"136","author":"Mao","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"2026010607271257800_ljaf347-B6","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1186\/s12889-022-13650-7","article-title":"Time-trends for eczema prevalences among children and adults from 1985 to 2015 in China: a systematic review","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Public Health"},{"key":"2026010607271257800_ljaf347-B7","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","article-title":"Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies","volume":"5","author":"Boguniewicz","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026010607271257800_ljaf347-B8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2026010607271257800_ljaf347-B9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"2026010607271257800_ljaf347-B10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jaip.2019.08.030","article-title":"Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study","volume":"8","author":"Schonmann","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026010607271257800_ljaf347-B11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bjd.17683","article-title":"Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults","volume":"181","author":"Silverberg","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026010607271257800_ljaf347-B12","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3389\/fpsyg.2019.01773","article-title":"Risk of mental disorders in children and adolescents with atopic dermatitis: a systematic review and meta-analysis","volume":"10","author":"Xie","year":"2019","journal-title":"Front Psychol"},{"key":"2026010607271257800_ljaf347-B13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026010607271257800_ljaf347-B14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"2026010607271257800_ljaf347-B15","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026010607271257800_ljaf347-B16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/JXX.0000000000000088","article-title":"Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: a pooled analysis of two phase 2 clinical trials","volume":"30","author":"Tofte","year":"2018","journal-title":"J Am Assoc Nurse Pract"},{"key":"2026010607271257800_ljaf347-B17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Tha\u00e7i","year":"2019","journal-title":"J Dermatol Sci"},{"key":"2026010607271257800_ljaf347-B18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjd.20690","article-title":"The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study","volume":"186","author":"Zhao","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026010607271257800_ljaf347-B19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2026010607271257800_ljaf347-B20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026010607271257800_ljaf347-B21","author":"Adtralza"},{"key":"2026010607271257800_ljaf347-B22"},{"key":"2026010607271257800_ljaf347-B23","author":"Ebglyss"},{"key":"2026010607271257800_ljaf347-B24","author":"EBGLYSS (lebrikizumab-lbkz), injection, for subcutaneous use"},{"key":"2026010607271257800_ljaf347-B25","author":"Dupixent"},{"key":"2026010607271257800_ljaf347-B26","author":"DUPIXENT\u00ae (dupilumab) injection, for subcutaneous use"},{"key":"2026010607271257800_ljaf347-B27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1080\/13696998.2024.2403940","article-title":"Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China","volume":"27","author":"Shi","year":"2024","journal-title":"J Med Econ"},{"key":"2026010607271257800_ljaf347-B28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026010607271257800_ljaf347-B29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/1744666X.2022.2039122","article-title":"Recent issues in JAK inhibitor safety: perspective for the clinician","volume":"18","author":"Fleischmann","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"2026010607271257800_ljaf347-B30","first-page":"6","article-title":"Dermatologic applications and safety considerations of Janus kinase inhibitors","volume":"25","author":"Svoboda","year":"2020","journal-title":"Skin Therapy Lett"},{"key":"2026010607271257800_ljaf347-B31","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/ijd.15853","article-title":"Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis","volume":"61","author":"Wood","year":"2022","journal-title":"Int J Dermatol"},{"key":"2026010607271257800_ljaf347-B32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/ITT.S229667","article-title":"Emerging role of Janus kinase inhibitors for the treatment of atopic dermatitis","volume":"9","author":"Singh","year":"2020","journal-title":"Immunotargets Ther"},{"key":"2026010607271257800_ljaf347-B33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40257-022-00701-3","article-title":"JAK in the [black] box: a dermatology perspective on systemic JAK inhibitor safety","volume":"23","author":"Elmariah","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2026010607271257800_ljaf347-B34","author":"RINVOQ (upadacitinib) extended-release tablets, for oral use."},{"key":"2026010607271257800_ljaf347-B35","doi-asserted-by":"crossref","first-page":"12411","DOI":"10.1038\/s41598-023-39311-2","article-title":"Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4R\u03b1, for the treatment of Th2 inflammatory diseases","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci Rep"},{"key":"2026010607271257800_ljaf347-B36","doi-asserted-by":"crossref","first-page":"A1397","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A1397","article-title":"Optimized second-generation IL-4R\u03b1 inhibition: structural and molecular dynamics properties of rademikibart Fab-IL-4R\u03b1 complex","volume":"211","author":"Collazo","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010607271257800_ljaf347-B37","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jaci.2023.11.924","article-title":"Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4R\u03b1, in adults with moderate to severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001)","volume":"153","author":"Silverberg","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2026010607271257800_ljaf347-B38","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/cts.13656","article-title":"Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4R\u03b1: two phase I randomized trials, in healthy individuals and patients with atopic dermatitis","volume":"16","author":"Wang","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2026010607271257800_ljaf347-B39","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.19457","article-title":"What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026010607271257800_ljaf347-B40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026010607271257800_ljaf347-B41","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010607271257800_ljaf347-B42","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-\u00adcontrolled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026010607271257800_ljaf347-B43","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2019.05.102","article-title":"Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: a systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026010607271257800_ljaf347-B44","first-page":"39","article-title":"Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score &lt;24 or \u226524","volume":"157","author":"Offidani","year":"2022","journal-title":"Ital J Dermatol Venerol"},{"key":"2026010607271257800_ljaf347-B45","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1007\/s13555-023-01052-5","article-title":"A mini review of the impact of baseline disease severity on clinical outcomes: should we compare atopic dermatitis clinical trials?","volume":"13","author":"Silverberg","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026010607271257800_ljaf347-B46","first-page":"804","article-title":"Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials","volume":"18","author":"Alexis","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"2026010607271257800_ljaf347-B47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","article-title":"The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment","volume":"20","author":"Facheris","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"2026010607271257800_ljaf347-B48","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjd.19751","article-title":"Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting","volume":"185","author":"Thomas","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026010607271257800_ljaf347-B49","doi-asserted-by":"crossref","first-page":"adv32323","DOI":"10.2340\/actadv.v104.32323","article-title":"Validation of the Recap of Atopic Eczema (RECAP) measurement instrument for eczema control in adult patients in an Asian clinical setting","volume":"104","author":"Yew","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"2026010607271257800_ljaf347-B50","first-page":"422","article-title":"Validation study of the Chinese version of atopic dermatitis control tool","volume":"57","author":"Luan","year":"2023","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"2026010607271257800_ljaf347-B51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","article-title":"EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference","volume":"67","author":"Schram","year":"2012","journal-title":"Allergy"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf347\/64194481\/ljaf347.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/1\/47\/64194481\/ljaf347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/1\/47\/64194481\/ljaf347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:27:23Z","timestamp":1767702443000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/1\/47\/8246129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,2]]},"published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf347","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,2]]}}}